ArticleTherapeutic advances in musculoskeletal disease2025
Development and evaluation of a multivariable prediction model for clinical improvement in an established cohort of Colombian rheumatoid arthritis patients.
Article in Therapeutic advances in musculoskeletal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease, and a predicting clinical improvement is essential. Objectives: The aim of the present study was to identify predictor variables of clinical improvement in patients with RA using artificial intelligence (AI) models in a specialized RA center. Design: Retrospective cohort study in adult RA patients was conducted between January and June 2022. Follow-up data related to clinical improvement was taken from 6 to 12 months after the baseline. Predictive models were generated by machine learning (ML), by Python programming language. The Transparent Reporting of a multivariate prediction model for Individual Prognosis or Diagnosis (TRIPOD) guidelines were followed to harmonize this study based on AI. Methods: The response variable was classified as improved and non-improved. Patients were considered improved if they persisted or achieved a Disease Activity Score 28-joints (DAS28) <3.2 at the end of the follow-up period or experienced a decrease ⩾0.6 compared to baseline, regardless of the initial DAS28 value. Explainability techniques in AI were applied to identify the most relevant clinical features. Results: In total, 3161 RA patients were included. The median age was 65 years (interquartile range (IQR) 57-72). 82.7% were female. Disease duration was 8.3 years (IQR 4.9-11.3). The median value of baseline DAS28 was 2.1 (IQR 2.1-2.8). 2668 (84.4%) were classified as improved, and 493 (15.6%) as non-improved. From ML models, the Extra tree model showed higher sensitivity (0.841). Regarding clinical improvement prediction with the Shapley Additive Explanations method, it was observed that low values of baseline DAS28 were positively associated with clinical improvement. The use of biologic disease-modifying antirheumatic drugs and the presence of anti-cyclic citrullinated peptide (CCP) were related to an increase in the probability of non-improved, which may be secondary to the level of severity of the disease. Conclusion: AI models in RA can predict clinical improvement at initial consultations, enabling targeted approaches. Disease severity may be influenced by anti-CCP positivity and the use of biologic therapies when conventional treatments fail.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.